vs
Cue Biopharma, Inc.（CUE）与Research Solutions, Inc.（RSSS）财务数据对比。点击上方公司名可切换其他公司
Cue Biopharma, Inc.的季度营收约是Research Solutions, Inc.的1.9倍（$21.9M vs $11.8M），Cue Biopharma, Inc.净利率更高（7.2% vs 4.6%，领先2.6%），Cue Biopharma, Inc.同比增速更快（1292.3% vs -1.0%），过去两年Cue Biopharma, Inc.的营收复合增速更高（257.5% vs -1.3%）
Cue Biopharma是一家临床阶段生物技术企业，专注于开发针对癌症、自身免疫性疾病和炎症疾病的新型靶向免疫疗法，其专有平台可精准调节T细胞活性，主要业务覆盖北美地区，与全球药企合作推进核心候选产品的临床试验。
雅各布斯解决方案是一家总部位于美国达拉斯的国际技术专业服务企业，面向全球各类客户（包括企业、机构及政府部门）提供工程、技术、专业、建筑相关服务，以及科研与专项咨询服务，常年位居《工程新闻纪录》顶级设计企业榜单榜首。
CUE vs RSSS — 直观对比
营收规模更大
CUE
是对方的1.9倍
$11.8M
营收增速更快
CUE
高出1293.3%
-1.0%
净利率更高
CUE
高出2.6%
4.6%
两年增速更快
CUE
近两年复合增速
-1.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $21.9M | $11.8M |
| 净利润 | $1.6M | $546.9K |
| 毛利率 | — | 52.4% |
| 营业利润率 | 9.0% | 6.3% |
| 净利率 | 7.2% | 4.6% |
| 营收同比 | 1292.3% | -1.0% |
| 净利润同比 | 116.7% | 127.6% |
| 每股收益（稀释后） | $0.05 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CUERSSS
| Q4 25 | $21.9M | $11.8M | ||
| Q3 25 | $2.1M | $12.3M | ||
| Q2 25 | $3.0M | $12.4M | ||
| Q1 25 | $421.0K | $12.7M | ||
| Q4 24 | $1.6M | $11.9M | ||
| Q3 24 | $3.3M | $12.0M | ||
| Q2 24 | $2.7M | $12.1M | ||
| Q1 24 | $1.7M | $12.1M |
净利润CUERSSS
| Q4 25 | $1.6M | $546.9K | ||
| Q3 25 | $-7.4M | $749.4K | ||
| Q2 25 | $-8.5M | $2.4M | ||
| Q1 25 | $-12.3M | $216.5K | ||
| Q4 24 | — | $-2.0M | ||
| Q3 24 | $-8.7M | $669.0K | ||
| Q2 24 | $-10.2M | $-2.8M | ||
| Q1 24 | $-12.3M | $76.3K |
毛利率CUERSSS
| Q4 25 | — | 52.4% | ||
| Q3 25 | — | 50.6% | ||
| Q2 25 | — | 51.0% | ||
| Q1 25 | — | 49.5% | ||
| Q4 24 | — | 48.9% | ||
| Q3 24 | — | 47.9% | ||
| Q2 24 | — | 46.5% | ||
| Q1 24 | — | 45.2% |
营业利润率CUERSSS
| Q4 25 | 9.0% | 6.3% | ||
| Q3 25 | -353.4% | 7.8% | ||
| Q2 25 | -292.3% | 9.7% | ||
| Q1 25 | -2921.4% | 4.4% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | -264.2% | 5.4% | ||
| Q2 24 | -390.6% | 5.5% | ||
| Q1 24 | -737.8% | 0.7% |
净利率CUERSSS
| Q4 25 | 7.2% | 4.6% | ||
| Q3 25 | -346.6% | 6.1% | ||
| Q2 25 | -287.1% | 19.0% | ||
| Q1 25 | -2911.4% | 1.7% | ||
| Q4 24 | — | -16.6% | ||
| Q3 24 | -259.6% | 5.6% | ||
| Q2 24 | -382.7% | -23.3% | ||
| Q1 24 | -719.1% | 0.6% |
每股收益（稀释后）CUERSSS
| Q4 25 | $0.05 | $0.02 | ||
| Q3 25 | $-0.07 | $0.02 | ||
| Q2 25 | $-0.09 | $0.08 | ||
| Q1 25 | $-0.17 | $0.01 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | $-0.17 | $0.02 | ||
| Q2 24 | $-0.20 | $-0.09 | ||
| Q1 24 | $-0.25 | $0.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.1M | $12.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $26.4M | $17.2M |
| 总资产 | $42.2M | $44.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CUERSSS
| Q4 25 | $27.1M | $12.3M | ||
| Q3 25 | $11.7M | $12.0M | ||
| Q2 25 | $27.5M | $12.2M | ||
| Q1 25 | $13.1M | $9.9M | ||
| Q4 24 | $22.5M | $7.7M | ||
| Q3 24 | $32.4M | $6.9M | ||
| Q2 24 | $30.0M | $6.1M | ||
| Q1 24 | $41.0M | $4.2M |
总债务CUERSSS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
股东权益CUERSSS
| Q4 25 | $26.4M | $17.2M | ||
| Q3 25 | $13.2M | $15.6M | ||
| Q2 25 | $18.2M | $13.9M | ||
| Q1 25 | $6.6M | $11.2M | ||
| Q4 24 | $17.5M | $11.1M | ||
| Q3 24 | $25.4M | $12.8M | ||
| Q2 24 | $21.6M | $11.7M | ||
| Q1 24 | $30.0M | $14.1M |
总资产CUERSSS
| Q4 25 | $42.2M | $44.2M | ||
| Q3 25 | $31.6M | $45.5M | ||
| Q2 25 | $40.7M | $46.1M | ||
| Q1 25 | $22.3M | $45.2M | ||
| Q4 24 | $32.2M | $42.8M | ||
| Q3 24 | $44.8M | $41.4M | ||
| Q2 24 | $42.3M | $41.9M | ||
| Q1 24 | $54.0M | $40.8M |
负债/权益比CUERSSS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.1M | $1.4M |
| 自由现金流经营现金流 - 资本支出 | — | $1.4M |
| 自由现金流率自由现金流/营收 | — | 11.7% |
| 资本支出强度资本支出/营收 | 0.0% | 0.1% |
| 现金转化率经营现金流/净利润 | -0.68× | 2.53× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CUERSSS
| Q4 25 | $-1.1M | $1.4M | ||
| Q3 25 | $-9.0M | $1.1M | ||
| Q2 25 | $-3.4M | $2.3M | ||
| Q1 25 | $-8.2M | $2.9M | ||
| Q4 24 | $-36.3M | $1.0M | ||
| Q3 24 | $-7.5M | $843.1K | ||
| Q2 24 | $-10.0M | $2.0M | ||
| Q1 24 | $-9.8M | $2.0M |
自由现金流CUERSSS
| Q4 25 | — | $1.4M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | $-3.4M | — | ||
| Q1 25 | $-8.3M | $2.9M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-7.5M | — | ||
| Q2 24 | $-10.0M | $1.9M | ||
| Q1 24 | $-9.8M | $2.0M |
自由现金流率CUERSSS
| Q4 25 | — | 11.7% | ||
| Q3 25 | — | 8.8% | ||
| Q2 25 | -116.5% | — | ||
| Q1 25 | -1976.7% | 22.8% | ||
| Q4 24 | -2309.3% | — | ||
| Q3 24 | -225.7% | — | ||
| Q2 24 | -376.2% | 16.0% | ||
| Q1 24 | -573.0% | 16.6% |
资本支出强度CUERSSS
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 35.6% | 0.0% | ||
| Q4 24 | 4.2% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.4% | 0.1% | ||
| Q1 24 | 3.2% | 0.0% |
现金转化率CUERSSS
| Q4 25 | -0.68× | 2.53× | ||
| Q3 25 | — | 1.48× | ||
| Q2 25 | — | 0.96× | ||
| Q1 25 | — | 13.36× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 26.43× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
RSSS
| Transactions | $6.6M | 56% |
| Platforms | $5.2M | 44% |
